BulkGLP Launches Multiple Retatrutide Vial Sizes 10mg 15mg 20mg 30mg to Meet Growing US Research Demand
United States, 27th Aug 2025 – BulkGLP, a Dallas-based supplier of high-purity research peptides, announced today the launch of multiple vial sizes of Retatrutide vials (10mg, 15mg, 20mg, 30mg), expanding availability to meet increasing demand among U.S. academic, clinical, and commercial research teams. Retatrutide (LY3437943), a triple-agonist peptide acting on GLP-1, GIP, and glucagon pathways, has drawn global attention as one of the most promising metabolic research compounds. With numerous studies exploring its potential in obesity, diabetes, and metabolic regulation,
Read more